Assembly and export of mycobacterial lipoglycans
Assembly and export of mycobacterial lipoglycans
批准号:
10620764
负责人:
Mary Jackson
金额:
$60.09万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-06-10 至 2026-05-31
关键词:
AbbreviationsActinobacteria classAcylationAcyltransferaseAnabolismBacillusBiochemicalBiochemistryBiogenesisBiologicalBiological AssayBlood capillariesCell membraneCell modelCell surfaceCellsChemicalsComplexCorynebacterium glutamicumDedicationsDevelopmentDiglyceridesDiseaseDissectionElectrophoresisEnzymesEsterificationEventFaceFamilyFatty AcidsGeneticGenomicsGenus MycobacteriumGlycerolGlycolipidsGoalsHIV/TBHumanHydroxyl RadicalImmune responseInositolInterventionInvestigationKnowledgeLaboratoriesLeprosyLigandsLipopolysaccharidesLocationMannansMannoseMannosidesMannosyltransferasesMass Spectrum AnalysisMembraneMetabolicMolecularMulti-Drug ResistanceMycobacterium tuberculosisNatureNomenclatureOpen Reading FramesOrganismPIM1 genePathogenesisPathway interactionsPhagocytesPharmaceutical PreparationsPhenotypePhosphatidylinositolsPhysiologyPlayPrevalencePreventionProcessRecombinantsResearchResortRoleSideSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationStreptomyces coelicolorStructureStructure-Activity RelationshipTherapeutic InterventionThin Layer ChromatographyTimeTuberculosisVaccinesVertebral columnVirulence FactorsXyloseacyl grouparabinogalactancell envelopeco-infectiondeoxycholatedesigndrug developmentenzyme activityenzyme pathwayepimeraseextensive drug resistancegenetic manipulationglycosylationglycosyltransferaseimmunoregulationinhaled nitric oxideinterestlipoarabinomannanlipomannanmutantmycobacterialmyoinositolnovelnovel therapeuticspathogenphosphatidylinositol mannosideprophylactictargeted treatmenttreatment strategytuberculosis drugs
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract
Phosphatidylinositol mannosides (PIM) and their multiglycosylated counterparts, lipomannan (LM) and
lipoarabinomannan (LAM), are complex glycolipids and lipoglycans found in the cell envelopes of all
mycobacterial species. They play various essential although poorly defined roles in mycobacterial physiology
and are important immunomodulatory molecules in the course of tuberculosis and leprosy as well as key
ligands promoting the entry of mycobacteria and their survival within phagocytic and non-phagocytic cells.
Although much progress has been made over the last 25 years in elucidating the structures and biosynthesis
of these molecules, fundamental questions remain about the pathways leading to their biosynthesis and
translocation to the cell surface. Furthermore, while the pleiotropic biological activities displayed by purified
PIM, LM and LAM in cellular models suggest that they play important roles in pathogenesis, studies aimed at
validating this assumption and precisely delineating their contribution to host-pathogen interactions when
carried by intact bacilli are still limited by the paucity of mutants deficient in well-defined aspects of the
biosynthesis and export of these molecules that are available.
We propose to pursue structural, genetic and biochemical studies toward a complete definition of the structure
(Aim 1), biosynthesis (Aim 2) and export (Aim 3) of PIM, LM and LAM. Completing our understanding of PIM,
LM and LAM biogenesis, in addition to providing fundamental knowledge about the biochemistry of
Mycobacterium tuberculosis (Mtb), is expected to lead to the discovery of essential enzymes and transporters
which, much like the arabinosyltransferases of the Emb family and the epimerase DprE1, could provide new
opportunities for anti-tuberculosis drug development. The availability of recombinant strains accumulating
structurally defined biosynthetic precursors will facilitate structure-function relationship studies, and that of
defined Mtb mutants deficient in various aspects of PIM, LM and LAM synthesis will allow a precise
assessment of the contribution of these molecules to the immunopathogenesis of tuberculosis.
Abbreviations:
AG, arabinogalactan; AM, arabinomannan; AcylT, acyltransferase; Araf, arabinofuranosyl; AraT, arabinosyltransferase; CZE, capillary
zone electrophoresis; DOC, deoxycholate; GT, glycosyltransferase; Ino, myo-Inositol; LAM, lipoarabinomannan; LM, lipomannan; LPS,
lipopolysaccharide; MALDI-TOF, Matrix-Assisted Laser desorption/ionization time of flight; Manp, mannopyranosyl; ManT,
mannosyltransferase; MPI, mannosylated phosphatidylinositol; MS, mass spectrometry; MTX, methyl-thio-xylose; ORF, open reading
frame; OM, outer membrane; PIM, phosphatidyl-myo-inositol mannosides; TLC, thin-layer chromatography.
Nomenclature:
PIM is used to describe the global family of phosphatidylinositol mannosides that carries one to four fatty acids (attached to the glycerol,
inositol and/or mannose) and one to six mannose residues. In AcXPIMY, x refers to the number of acyl groups esterified to available
hydroxyls on the mannose or myo-inositol residues, y refers to the number of mannose residues; e.g. Ac1PIM1 corresponds to the
phosphatidylinositol mono-mannoside PIM1 carrying two acyl groups attached to the glycerol (the diacylglycerol substituent) and one
acyl group esterified to the mannose residue.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1038/s41467-023-42478-x
发表时间:
2023-10-23
期刊:
Nature communications
影响因子:
16.6
作者:
[Angala SK, Carreras-Gonzalez A, Huc-Claustre E, Anso I, Kaur D, Jones V, Palčeková Z, Belardinelli JM, de Sousa-d'Auria C, Shi L, Slama N, Houssin C, Quémard A, McNeil M, Guerin ME, Jackson M]
通讯作者:
Jackson M
DOI:
10.1126/sciadv.adh7957
发表时间:
2024-01-05
期刊:
SCIENCE ADVANCES
影响因子:
13.6
作者:
[Eskandarian, Haig Alexander, Chen, Yu-Xiang, Toniolo, Chiara, Belardinelli, Juan M., Palcekova, Zuzana, Hom, Lesley, Ashby, Paul D., Fantner, Georg E., Jackson, Mary, Mckinney, John D., Javid, Babak]
通讯作者:
Javid, Babak
Repurposing antimalarials for the treatment of NTM infections
-
批准号:10646331
-
项目类别:
-
资助金额:$66.63万
-
财政年份:2022
-
负责人:Mary Jackson
-
依托单位:
Repurposing antimalarials for the treatment of NTM infections
-
批准号:10494711
-
项目类别:
-
资助金额:$64.52万
-
财政年份:2022
-
负责人:Mary Jackson
-
依托单位:
Assembly and export of mycobacterial lipoglycans
-
批准号:10291355
-
项目类别:
-
资助金额:$67.65万
-
财政年份:2021
-
负责人:Mary Jackson
-
依托单位:
Assembly and export of mycobacterial lipoglycans
-
批准号:10426356
-
项目类别:
-
资助金额:$66.35万
-
财政年份:2021
-
负责人:Mary Jackson
-
依托单位:
Adjunct therapeutic potential of a repurposed drug inhibiting Mycobacterium abscessus biofilm formation
-
批准号:10172839
-
项目类别:
-
资助金额:$19.0万
-
财政年份:2020
-
负责人:Mary Jackson
-
依托单位:
Inhibitors of Mycobacterium tuberculosis FAS-II dehydratases
-
批准号:10190829
-
项目类别:
-
资助金额:$20.02万
-
财政年份:2020
-
负责人:Mary Jackson
-
依托单位:
Recombinant BCG-based SARS-CoV-2 vaccine
-
批准号:10171055
-
项目类别:
-
资助金额:$41.2万
-
财政年份:2020
-
负责人:Mary Jackson
-
依托单位:
Inhibitors of Mycobacterium tuberculosis FAS-II dehydratases
-
批准号:10038295
-
项目类别:
-
资助金额:$17.58万
-
财政年份:2020
-
负责人:Mary Jackson
-
依托单位:
2019 Tuberculosis Drug Discovery and Development GRC: Shortening the Duration of Tuberculosis Chemotherapy and GRS
-
批准号:9750348
-
项目类别:
-
资助金额:$0.6万
-
财政年份:2019
-
负责人:Mary Jackson
-
依托单位:
Mechanisms of Susceptibility and Resistance of Mycobacterium tuberculosis to Isoxyl and Thiacetazone
-
批准号:9303706
-
项目类别:
-
资助金额:$20.81万
-
财政年份:2017
-
负责人:Mary Jackson
-
依托单位:
Mycobacterium Tuberculosis Cell Wall Assembly
-
批准号:9089894
-
项目类别:
-
资助金额:$22.65万
-
财政年份:2015
-
负责人:Mary Jackson
-
依托单位:
MmpL3 as a target for novel anti-TB agents
-
批准号:10583474
-
项目类别:
-
资助金额:$62.83万
-
财政年份:2015
-
负责人:Mary Jackson
-
依托单位:
MmpL3 as a target for novel anti-TB agents
-
批准号:9089910
-
项目类别:
-
资助金额:$50.72万
-
财政年份:2015
-
负责人:Mary Jackson
-
依托单位:
MmpL3 as a target for novel anti-TB agents
-
批准号:10372133
-
项目类别:
-
资助金额:$62.83万
-
财政年份:2015
-
负责人:Mary Jackson
-
依托单位:
MmpL3 as a target for novel anti-TB agents
-
批准号:9276565
-
项目类别:
-
资助金额:$51.36万
-
财政年份:2015
-
负责人:Mary Jackson
-
依托单位:
Mycobacterium Tuberculosis Cell Wall Assembly
-
批准号:8938582
-
项目类别:
-
资助金额:$18.75万
-
财政年份:2015
-
负责人:Mary Jackson
-
依托单位:
Disinfectant-resistant mycobacteria
-
批准号:8424281
-
项目类别:
-
资助金额:$33.41万
-
财政年份:2011
-
负责人:Mary Jackson
-
依托单位:
Disinfectant-resistant mycobacteria
-
批准号:8102642
-
项目类别:
-
资助金额:$36.54万
-
财政年份:2011
-
负责人:Mary Jackson
-
依托单位:
Disinfectant-resistant mycobacteria
-
批准号:8234961
-
项目类别:
-
资助金额:$35.36万
-
财政年份:2011
-
负责人:Mary Jackson
-
依托单位:
Disinfectant-resistant mycobacteria
-
批准号:8644781
-
项目类别:
-
资助金额:$35.54万
-
财政年份:2011
-
负责人:Mary Jackson
-
依托单位: